A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)

NCT06735755 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Glycogen Storage Disease Type Ia

Interventions

DRUG: BEAM-301: Single dose of BEAM-301 administered by IV

Sponsor

Beam Therapeutics Inc.